Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 15/20 | 0.50 |
| ▸ | IGF1R | P08069 | 7/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.47 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25262307 | 1.00 | ALK (0.50) | ALKIGF1RMAP4K4HRH4HRH3 | |
| SCHEMBL29438256 | 0.88 | SHMT2 (0.49) | ALKIGF1RMAP4K4ALDH1A1 | |
| SCHEMBL23582494 | 0.87 | HRH4 (0.46) | HRH4HRH3KDM4E | |
| SCHEMBL12184979 | 0.82 | ALK (0.51) | ALKIGF1RHRH4HRH3KDM4E | |
| SCHEMBL23582215 | 0.77 | ALDH1A1 (0.48) | HRH4HRH3KDM4EMEN1ALDH1A1 | |
| SCHEMBL23582548 | 0.77 | HRH3 (0.52) | ALKIGF1RHRH4HRH3KDM4E | |
| SCHEMBL23582547 | 0.77 | HRH3 (0.52) | ALKIGF1RHRH4HRH3KDM4E | |
| SCHEMBL2634994 | 0.75 | ALK (0.81) | ALKIGF1R | |
| SCHEMBL2635004 | 0.75 | ALK (0.81) | ALKIGF1R | |
| SCHEMBL2635264 | 0.75 | ALK (0.81) | ALKIGF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322706-A1 | NOVEL BIARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF | LG CHEM, LTD. (KR) | 2023-10-12 | — | — | US | disclosed |
| EP-4206193-A1 | NOVEL BIARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF | Lg Chem, Ltd. (KR) | 2023-07-05 | — | — | EP | disclosed |
| CN-116056706-A | Novel biaryl derivatives useful as diacylglycerol acyltransferase 2 inhibitors and uses thereof | 株式会社LG化学 | 2023-05-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322706-A1 | NOVEL BIARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF | DGAT2, DGAT1, MOGAT2 | ALK 2517/4885IGF1R 3902/4885MAP4K4 3593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.